Home › Research › Biomarkers
Blood phosphorylated Tau181 reliably differentiates amyloid-positive from amyloid-negative subjects in the Alzheimer's disease continuum: A systematic review and meta-analysis
Antonioni A, Raho EM, Manzoli L, Koch G, Flacco ME, Di Lorenzo F.. Alzheimer's & dementia (Amsterdam, Netherlands), 2025-01-16
Topic: Amyloid, tau and blood-test diagnosis
Introduction Blood-based biomarkers seem promising for the diagnosis of Alzheimer's disease (AD). Methods We performed a systematic review and meta-analysis on the potential of blood phosphorylated Tau181 (p-tau181) to differentiate amyloid-positive (A+) and amyloid-negative (A-) subjects. Two meta-analyses were conducted, showing the mean p-tau values in blood and cerebrospinal fluid (CSF) in the A+ and A- group, and the second comparing the mean p-tau concentrations in blood and CSF among A+ versus A- participants, by laboratory assessment method. Results Eighteen studies (2764 A+ and 5646 A- subjects) were included. The single-group meta-analysis showed mean higher blood p-tau181 values in the A+ than in the A- group. In the head-to-head meta-analysis, blood p-tau reliably differentiated A+ patients from A- participants. Discussion Regardless of the laboratory technique, blood p-tau181 reliably differentiates A+ and A- subjects. Therefore, it might have important applications for early diagnosis and inclusion in clinical trials for AD patients. Highlights The role of blood-based biomarkers in discriminating AD patients is still uncertain.Blood p-tau181 distinguishes among amyloid-positive and amyloid-negative subjects.Blood p-tau181 might allow early diagnosis and inclusion in clinical trials.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Antonioni, A., Raho, E. M., Manzoli, L., Koch, G., Flacco, M. E., & Di Lorenzo, F. (2025). Blood phosphorylated Tau181 reliably differentiates amyloid-positive from amyloid-negative subjects in the Alzheimer's disease continuum: A systematic review and meta-analysis. Alzheimer's & dementia (Amsterdam, Netherlands). https://doi.org/10.1002/dad2.70068
Vancouver
Antonioni A, Raho EM, Manzoli L, Koch G, Flacco ME, Di Lorenzo F. Blood phosphorylated Tau181 reliably differentiates amyloid-positive from amyloid-negative subjects in the Alzheimer's disease continuum: A systematic review and meta-analysis. Alzheimer's & dementia (Amsterdam, Netherlands). 2025. doi:10.1002/dad2.70068. PMID: 39822285.
BibTeX
@article{antonioni2025-39822285,
author = {Antonioni, A. and Raho, E. M. and Manzoli, L. and Koch, G. and Flacco, M. E. and Di Lorenzo, F.},
title = {{Blood phosphorylated Tau181 reliably differentiates amyloid-positive from amyloid-negative subjects in the Alzheimer's disease continuum: A systematic review and meta-analysis}},
journal = {Alzheimer's \& dementia (Amsterdam, Netherlands)},
year = {2025},
doi = {10.1002/dad2.70068},
pmid = {39822285},
url = {https://doi.org/10.1002/dad2.70068}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Two meta-analyses were conducted, showing the mean p-tau values in blood and cerebrospinal fluid (CSF) in the A+ and A- group, and the second comparing the mean p-tau concentrations in blood and CSF among A+ versus A- participants, by laboratory assessment method.
- Results Eighteen studies (2764 A+ and 5646 A- subjects) were included.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designsystematic review
- Evidence strengthHigh
How this study scored 76/100
Published in a leading specialty journal, and it is a systematic review of all the studies on the question. Scored zero for sample size, effect reported and studied in people because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 44 of the 58 points we could judge it on, which is 76 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia (Amsterdam, Netherlands)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | A review of other studies — randomisation is not credited here |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39822285) |
| Free to read | 2 / 2 | Free to read |
| Points | 44 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 44 of the 58 points we could judge it on is 76 out of 100. |
| Total | 76 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.